SMO and neoplasm: Approximately half of meningioma cases carry NF2 aberrations and recent studies have identified other recurring molecular alterations such as AKT mutations, SMO mutations, PI3K mutations, TERT promoter mutations, and gene promoter methylation profiles that show strong correlations with tumor location, tumor histology, and clinical course.